{"id":"https://genegraph.clinicalgenome.org/r/aaf4cac0-d90a-4d49-b2b9-0ab0f4fb2f81v1.0","type":"EvidenceStrengthAssertion","dc:description":"Human pathogenic *PPARG* variants were first reported in autosomal dominantly inherited severe insulin resistance in 1999 (Barroso et al, PMID:10622252), attributed to lipodystrophy shortly afterwards (Agarwal et al, PMID: 11788685). We have now curated the inheritance pattern for *PPARG*-related lipodystrophy as semidominant because, while most cases are autosomal dominant, very rarely a recessive mode of inheritance has been reported (Dyment et al, PMID:24980513; Gosseaume et al, PMID:36806620). \n\nBoth loss of function and dominant negative variants have been reported.  Typical autosomal dominant cases due to heterozygous variants present with loss of subcutaneous adipose tissue, especially of the limbs, and metabolic complications, in a form of familial partial lipodystrophy (Chen et al et al, PMID:35422762; PMID:36806620; Vasandani et al, PMID:36397776). The occasional recessive cases typically feature early-onset, congenital generalized lipodystrophy, also known as Berardinelli-Seip syndrome, due to biallelic variants in *PPARG* (PMIDs:24980513, 36806620). \n\nAt least 60 lipodystrophy-causing *PPARG* variants (primarily missense) have been reported in humans. Evidence supporting the association of this gene with lipodystrophy includes case-level data, segregation data, and experimental data. **The aggregated score for case-level and segregation data is 12 points.** Variants in this gene have been reported in at least 35 probands in 14 publications (PMIDs: 17766367, 24980513, 16965332, 10622252, 17299075, 29622583, 35422762, 17011503, 12453919, 11788685, 22750678, 34168618, 36806620, 36397776), with most cases presenting as familial partial lipodystrophy and two cases with congenital, generalized lipodystrophy. More evidence is available to support the gene-disease association in the literature, but as the maximum score for genetic evidence (12 points) has been reached this has not been curated exhaustively. This gene-disease relationship is supported by functional assays (both individual and massively parallel), expression studies and functional alterations. **Total points for the experimental evidence are 4. Total points for genetic and experimental evidence together are thus 16.**\n\nPer criteria outlined by the ClinGen Lumping and Splitting Working Group, we found both differences in inheritance pattern and phenotypic variability, but also overlap in the implicated variants. Specifically, *PPARG* has two associated diseases, namely the more commonly associated autosomal dominant familial partial lipodystrophy (OMIM:604367), and the more rarely associated autosomal recessive congenital, generalized lipodystrophy.  Because the latter is rare and there is overlap in the implicated variants, these two entities have been lumped in a single curation of lipodystrophy (MONDO: 0006573).  \n\nIn summary, *PPARG* is definitively associated with semidominant lipodystrophy, with most cases presenting as autosomal dominant familial partial lipodystrophy in adolescents and young adults. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time.\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/aaf4cac0-d90a-4d49-b2b9-0ab0f4fb2f81","GCISnapshot":"https://genegraph.clinicalgenome.org/r/b4c76c1c-7e8a-418f-ba62-b7eeb3c3d472","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/b4c76c1c-7e8a-418f-ba62-b7eeb3c3d472_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10016","date":"2024-08-14T17:48:17.650Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/b4c76c1c-7e8a-418f-ba62-b7eeb3c3d472_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10016","date":"2024-08-14T16:00:00.000Z","role":"Approver"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b4c76c1c-7e8a-418f-ba62-b7eeb3c3d472_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/158ddd0c-8fbe-49bb-9494-c7b14c58923f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/06d6913b-3a1d-4692-97bb-7b871520fa42","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/06d6913b-3a1d-4692-97bb-7b871520fa42_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"V290M mutant markedly attenuated the transcriptional function of wildtype PPARg and showed dominant-negative activity in 293EBNA transfected cells. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/06d6913b-3a1d-4692-97bb-7b871520fa42_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10622252","allele":{"id":"https://genegraph.clinicalgenome.org/r/331b1392-1441-49a0-bd75-d56887c6a387","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.862G>A (p.Val288Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119321"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/158ddd0c-8fbe-49bb-9494-c7b14c58923f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10622252","rdfs:label":"Barroso Proband 2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/331b1392-1441-49a0-bd75-d56887c6a387"},"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/06d6913b-3a1d-4692-97bb-7b871520fa42_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/166164c7-8002-43a2-9bc8-c6450f9183a1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5ee5aed5-35f5-4b6f-b002-091394ddaa88","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5ee5aed5-35f5-4b6f-b002-091394ddaa88_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro transfection assays using reporter constructs containing either synthetic {(PPARE)3 TKLUC} or natural (human FABP4-LUC) enhancer/promoter elements, The Ala261Glu mutant exhibit negligible basal transcriptional activity and minimal responsiveness with PGJ2. However, moderate (100nM farglitazar) or higher concentrations (1µM rosiglitazone; 10µM pioglitazone) of synthetic agonists restored transcriptional activity comparable to wild type receptor.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5ee5aed5-35f5-4b6f-b002-091394ddaa88_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29622583","allele":{"id":"https://genegraph.clinicalgenome.org/r/b5862379-b779-47ee-a27f-b444e73be9a6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.692C>A (p.Ala231Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351618934"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/166164c7-8002-43a2-9bc8-c6450f9183a1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29622583","rdfs:label":"Agostini proband 2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":20,"allele":{"id":"https://genegraph.clinicalgenome.org/r/b5862379-b779-47ee-a27f-b444e73be9a6"},"detectionMethod":"DNA from the patient, mother and siblings was sequenced for the PPARG and LMNA genes.","firstTestingMethod":"PCR","phenotypes":["obo:HP_0003712","obo:HP_0001397","obo:HP_0000831","obo:HP_0003635","obo:HP_0003124"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/5ee5aed5-35f5-4b6f-b002-091394ddaa88_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/75a11eaf-597e-439d-9e8d-5048710942ec_proband_score_evidence_line","type":"EvidenceLine","direction":"Inconclusive","specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b4c76c1c-7e8a-418f-ba62-b7eeb3c3d472_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6bd02155-c145-46ae-8bea-5fd6a10b7846_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36806620","rdfs:label":"Gosseaume family 3","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/6bd02155-c145-46ae-8bea-5fd6a10b7846","type":"Family","rdfs:label":"Gosseaume family 3","member":{"id":"https://genegraph.clinicalgenome.org/r/0c3e2edd-b494-4426-b997-4910c0ac0aee","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36806620","rdfs:label":"Gosseaume proband 3","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":10,"allele":{"id":"https://genegraph.clinicalgenome.org/r/38e613d5-0f0b-4e87-94ef-96577084a5d2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.926T>A (p.Leu309Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351619537"}},"detectionMethod":"Targeted NGS panel for 23 Lipodystrophy-dedicated genes followed by sanger sequencing of PPARg variants","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Next generation sequencing panels","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/360ca6b0-007c-405d-9416-f18cb2ca9148_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36806620","allele":{"id":"https://genegraph.clinicalgenome.org/r/38e613d5-0f0b-4e87-94ef-96577084a5d2"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0000956","obo:HP_0009017","obo:HP_0002155","obo:HP_0000822","obo:HP_0003124","obo:HP_0000831","obo:HP_0000292"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/0c3e2edd-b494-4426-b997-4910c0ac0aee"}},{"id":"https://genegraph.clinicalgenome.org/r/98a60484-de4d-4c1c-a5a5-2cc0bb761d5b_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11788685","rdfs:label":"Agarwal Family 1","family":{"id":"https://genegraph.clinicalgenome.org/r/98a60484-de4d-4c1c-a5a5-2cc0bb761d5b","type":"Family","rdfs:label":"Agarwal Family 1","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/96901dd9-0c3c-4703-954d-5c0b1cbe8257","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11788685","rdfs:label":"Agarwal Proband1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":32,"allele":{"id":"https://genegraph.clinicalgenome.org/r/76ced8a2-6982-43fa-abb7-607ab729868f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.1183C>T (p.Arg395Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119328"}},"detectionMethod":"Single gene sequencing was performed for the PPARg gene using gene specific primers","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3379ec50-399d-4b82-af96-28e9efcb243e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11788685","allele":{"id":"https://genegraph.clinicalgenome.org/r/76ced8a2-6982-43fa-abb7-607ab729868f"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002155","obo:HP_0009017","obo:HP_0000956","obo:HP_0003233","obo:HP_0000292","obo:HP_0005978","obo:HP_0003124","obo:HP_0000842","obo:HP_0000831","obo:HP_0000855"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/96901dd9-0c3c-4703-954d-5c0b1cbe8257"}},{"id":"https://genegraph.clinicalgenome.org/r/3324186e-bac7-4cab-a3ca-e79f64913481_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17766367","rdfs:label":"Lüdtke etal _family 1.2","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/3324186e-bac7-4cab-a3ca-e79f64913481","type":"Family","rdfs:label":"Lüdtke etal _family 1.2","member":{"id":"https://genegraph.clinicalgenome.org/r/faf2beb8-3d8c-43d1-a5a5-f998e2a46532","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17766367","rdfs:label":"Lüdtke proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":14,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a259c156-bb1e-4441-bf48-9fc917dacdff","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.1180G>A (p.Asp394Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351620115"}},"detectionMethod":"DNA was isolated from blood samples. LMNA and PPARG gene was PCR amplified and directly sequenced.  The mutation within PPARG was confirmed by restriction fragment length polymorphism analysis using MnII.\n","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0003635","obo:HP_0003712","obo:HP_0003124","obo:HP_0001397","obo:HP_0000831"],"previousTesting":false,"secondTestingMethod":"Restriction digest","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3c21cc79-414f-4ae4-a6d7-e157b1305f8f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17766367","allele":{"id":"https://genegraph.clinicalgenome.org/r/a259c156-bb1e-4441-bf48-9fc917dacdff"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0003124","obo:HP_0001397","obo:HP_0003635","obo:HP_0000831","obo:HP_0003712"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/faf2beb8-3d8c-43d1-a5a5-f998e2a46532"}},{"id":"https://genegraph.clinicalgenome.org/r/e16426f5-accb-4104-9b29-51ac81c73627_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17011503","rdfs:label":"Agostini Family S5","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/e16426f5-accb-4104-9b29-51ac81c73627","type":"Family","rdfs:label":"Agostini Family S5","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/6395d6cf-df8e-4c31-9a09-95a9f077254c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17011503","rdfs:label":" Agostini Proband S5","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":26,"allele":{"id":"https://genegraph.clinicalgenome.org/r/3143b3ea-ef2e-47dc-a146-d05c54c341fc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.1063C>T (p.Arg355Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351619846"}},"firstTestingMethod":"Sanger sequencing","secondTestingMethod":"Genotyping","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/8dc7a6c4-6cf2-4577-9bfd-72a83e81b17e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17011503","allele":{"id":"https://genegraph.clinicalgenome.org/r/3143b3ea-ef2e-47dc-a146-d05c54c341fc"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0000831","obo:HP_0003124","obo:HP_0000842","obo:HP_0003233","obo:HP_0000956","obo:HP_0005978","obo:HP_0000292","obo:HP_0000855","obo:HP_0009017","obo:HP_0002155"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/6395d6cf-df8e-4c31-9a09-95a9f077254c"}},{"id":"https://genegraph.clinicalgenome.org/r/3eb050aa-539e-4bb8-97cf-0dd32c1ee13f_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36402763","rdfs:label":"Madsen  family 2","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/3eb050aa-539e-4bb8-97cf-0dd32c1ee13f","type":"Family","rdfs:label":"Madsen  family 2","cg:modeOfInheritance":"Autosomal dominant/X-linked"},"meetsInclusionCriteria":false,"phenotypeFreeText":"subcutaneous fat on the face, neck, trunk, and abdomen with a lack of subcutaneous fat on the extremities, Insulin resistance, diabetes mellitus, Acanthosis nigricans, hypertension and hypertriglyceridaemia.","phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0000831","obo:HP_0003635","obo:HP_0001397","obo:HP_0003712","obo:HP_0003124"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/cfeeaaf4-1540-4e32-9d8c-3864e7892740"}},{"id":"https://genegraph.clinicalgenome.org/r/04e6d530-9e08-4d76-94a2-7f16a40038e7_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12453919","rdfs:label":"Hegele family","family":{"id":"https://genegraph.clinicalgenome.org/r/04e6d530-9e08-4d76-94a2-7f16a40038e7","type":"Family","rdfs:label":"Hegele family","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/5be60c3a-f857-4ab8-a41b-72a7768a7755","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12453919","rdfs:label":"Hegele proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":46,"allele":{"id":"https://genegraph.clinicalgenome.org/r/ef51fd72-32f4-4b7e-857c-12e7cbe6aaf0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.1074T>A (p.Phe358Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119326"}},"ethnicity":{"id":"cg:UnknownEthnicity"},"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/c4d1786d-ff9a-4fea-a78e-25d62d9883e1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12453919","allele":{"id":"https://genegraph.clinicalgenome.org/r/ef51fd72-32f4-4b7e-857c-12e7cbe6aaf0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"meetsInclusionCriteria":false,"phenotypeFreeText":"Affected subjects have total or partial loss of subcutaneous adipose tissue from extremities, with sparing of head, neck, and abdominal fat depots, and multiple metabolic disturbances including insulin resistance, diabetes, and dyslipidemia.","phenotypes":["obo:HP_0003635","obo:HP_0000822","obo:HP_0003124","obo:HP_0002155","obo:HP_0005978","obo:HP_0000831"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/5be60c3a-f857-4ab8-a41b-72a7768a7755"},"publishedLodScore":2.11},{"id":"https://genegraph.clinicalgenome.org/r/22d6c07c-a017-4370-9681-3176f84dacfa_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36402763","rdfs:label":"Madsen  family 1","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/22d6c07c-a017-4370-9681-3176f84dacfa","type":"Family","rdfs:label":"Madsen  family 1","cg:modeOfInheritance":"Autosomal dominant/X-linked"},"meetsInclusionCriteria":true,"phenotypeFreeText":"A clear excess of subcutaneous fat on the face, neck, trunk, and abdomen with a lack of subcutaneous fat on the extremities, Insulin resistance, diabetes mellitus, Acanthosis nigricans, hypertension and hypertriglyceridaemia.","phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0003635","obo:HP_0003124","obo:HP_0000831","obo:HP_0003712","obo:HP_0001397"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/ca37cdd4-cc9a-481d-ba55-8ff3a316de21"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/8a7b1a58-1ea0-4ecc-b135-aeb6ed01564e_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30595551","rdfs:label":"Broekema family","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/8a7b1a58-1ea0-4ecc-b135-aeb6ed01564e","type":"Family","rdfs:label":"Broekema family","ethnicity":{"id":"cg:UnknownEthnicity"},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0003124","obo:HP_0000831","obo:HP_0001397","obo:HP_0003712","obo:HP_0003635"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/75a11eaf-597e-439d-9e8d-5048710942ec"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/fb3167dd-eed0-4b06-b4e2-8b23990a2c4c_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36806620","rdfs:label":"Gosseaume family 10","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/fb3167dd-eed0-4b06-b4e2-8b23990a2c4c","type":"Family","rdfs:label":"Gosseaume family 10","member":{"id":"https://genegraph.clinicalgenome.org/r/1fb38743-e7dc-4b29-a135-481706bd0582","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36806620","rdfs:label":"Gosseaume proband 17","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/144aec8d-ec78-4c44-a697-56bb1c9570d7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.428A>G (p.Tyr143Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2258199"}},"detectionMethod":"Targeted NGS panel for 23 Lipodystrophy-dedicated genes followed by sanger sequencing of PPARg variants","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Next generation sequencing panels","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/1489bb79-f3ad-4588-8881-3772ec878ecc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36806620","allele":{"id":"https://genegraph.clinicalgenome.org/r/144aec8d-ec78-4c44-a697-56bb1c9570d7"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:BiallelicHomozygous"}},"zygosity":{"id":"cg:BiallelicHomozygous"}},"cg:modeOfInheritance":"Semidominant"},"phenotypes":["obo:HP_0003124","obo:HP_0000831","obo:HP_0002155","obo:HP_0009017","obo:HP_0000822","obo:HP_0000292","obo:HP_0000956"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/1fb38743-e7dc-4b29-a135-481706bd0582"}},{"id":"https://genegraph.clinicalgenome.org/r/fab04469-6efa-4c14-98eb-acea7c855a46_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10622252","rdfs:label":"Barroso et al _Kindred B","family":{"id":"https://genegraph.clinicalgenome.org/r/fab04469-6efa-4c14-98eb-acea7c855a46","type":"Family","rdfs:label":"Barroso et al _Kindred B","member":{"id":"https://genegraph.clinicalgenome.org/r/158ddd0c-8fbe-49bb-9494-c7b14c58923f"}},"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0001397","obo:HP_0003124","obo:HP_0003712","obo:HP_0003635","obo:HP_0000831"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/158ddd0c-8fbe-49bb-9494-c7b14c58923f"}},{"id":"https://genegraph.clinicalgenome.org/r/7ba29665-2f39-4224-92bd-100ec788bc5f_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17011503","rdfs:label":"Agostini Family S1","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/7ba29665-2f39-4224-92bd-100ec788bc5f","type":"Family","rdfs:label":"Agostini Family S1","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/a1d7bf7c-bb71-483e-9e13-bba6d4bf23cd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17011503","rdfs:label":"Agostini proband S1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":34,"allele":{"id":"https://genegraph.clinicalgenome.org/r/da24653a-ec1d-4ff3-a54f-2075afd38041","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.334T>C (p.Cys112Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351618093"}},"detectionMethod":"The PPP1R3A (exons 1-4) and PPARγ (exons 1-6) and promoter region of PPARγ4 genes were PCR amplified using specific primers.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Sanger sequencing","previousTesting":false,"secondTestingMethod":"Genotyping","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d6180eef-2c27-4fa2-b149-6f68c4bd390e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17011503","allele":{"id":"https://genegraph.clinicalgenome.org/r/da24653a-ec1d-4ff3-a54f-2075afd38041"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0008887","obo:HP_0000006","obo:HP_0000855","obo:HP_0005978","obo:HP_0000956","obo:HP_0003124","obo:HP_0000822","obo:HP_0003233","obo:HP_0003758","obo:HP_0000842","obo:HP_0003635"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/a1d7bf7c-bb71-483e-9e13-bba6d4bf23cd"}},{"id":"https://genegraph.clinicalgenome.org/r/bf133406-c859-4693-bd60-2560ef765b79_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17011503","rdfs:label":"Agostini Family S3","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/bf133406-c859-4693-bd60-2560ef765b79","type":"Family","rdfs:label":"Agostini Family S3","member":{"id":"https://genegraph.clinicalgenome.org/r/b660a33b-d7a8-4094-a566-5402351f9663","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17011503","rdfs:label":"Agostini Proband S3","allele":{"id":"https://genegraph.clinicalgenome.org/r/2139040e-578c-4728-854d-0212d6af19c3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.480T>G (p.Cys160Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351618445"}},"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/18beee2a-78dd-4ef3-bc53-b44411fb9eaf_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17011503","allele":{"id":"https://genegraph.clinicalgenome.org/r/2139040e-578c-4728-854d-0212d6af19c3"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0002155","obo:HP_0000855","obo:HP_0003233","obo:HP_0000831","obo:HP_0005978","obo:HP_0003124","obo:HP_0000956","obo:HP_0009017","obo:HP_0000292","obo:HP_0000842"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/b660a33b-d7a8-4094-a566-5402351f9663"}},{"id":"https://genegraph.clinicalgenome.org/r/4d317753-5916-4962-87dc-83c9f304e871_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22750678","rdfs:label":"Campeau  Family","estimatedLodScore":4.21,"family":{"id":"https://genegraph.clinicalgenome.org/r/4d317753-5916-4962-87dc-83c9f304e871","type":"Family","rdfs:label":"Campeau  Family","member":{"id":"https://genegraph.clinicalgenome.org/r/25564d13-fcc9-4c77-bdd0-0419ac5a0099","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22750678","rdfs:label":"Campeau proband 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":45,"allele":{"id":"https://genegraph.clinicalgenome.org/r/0a19459d-9eb6-4452-ad47-41408ce31eb0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.381A>C (p.Glu127Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351618204"}},"detectionMethod":"PCR amplification of six exons of PPARG plus at least 100 nucleotides at each intron-exon boundary and ∼700 bp of the promoter were sequenced. In addition, LPL gene common polymorphism D9N, and APOE  genotypes were assessed.\n\n\n","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Campeau et al 2012 described a family with a severe form of FPLD3 with novel features including muscle pseudohypertrophy and myopathy, neuropathy, multiple cytopenias and susceptibility to autoimmune disease.","phenotypes":["obo:HP_0005978","obo:HP_0000855","obo:HP_0000956","obo:HP_0000831","obo:HP_0002155","obo:HP_0000842","obo:HP_0009017","obo:HP_0003233","obo:HP_0003124","obo:HP_0000292"],"previousTesting":false,"secondTestingMethod":"Genotyping","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/c471b547-8523-4617-9aa3-7de15a030b0e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22750678","allele":{"id":"https://genegraph.clinicalgenome.org/r/0a19459d-9eb6-4452-ad47-41408ce31eb0"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"meetsInclusionCriteria":true,"phenotypeFreeText":"Campeau et al 2012 described a family with a severe form of FPLD3 with novel features including muscle pseudohypertrophy and myopathy, neuropathy, multiple cytopenias and susceptibility to autoimmune disease.","phenotypePositiveAllelePositive":14,"phenotypes":["obo:HP_0000292","obo:HP_0000842","obo:HP_0009017","obo:HP_0000855","obo:HP_0000831","obo:HP_0000956","obo:HP_0003233","obo:HP_0002155","obo:HP_0003124","obo:HP_0005978"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/25564d13-fcc9-4c77-bdd0-0419ac5a0099"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/4089f2fc-8e31-41ba-a6a1-7df500a4d3ae_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10622252","rdfs:label":"Barroso Kindred A","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/4089f2fc-8e31-41ba-a6a1-7df500a4d3ae","type":"Family","rdfs:label":"Barroso Kindred A","member":{"id":"https://genegraph.clinicalgenome.org/r/72a8cf92-f6e6-4710-be34-ec67bbda874c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10622252","rdfs:label":"Barroso Proband1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":20,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f9e4539c-7a79-47e9-8498-92f6c266dfe4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.1394C>T (p.Pro465Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119319"}},"detectionMethod":"All coding exons of PPARg1 and PPARg2 were amplified using polymerase chain reaction (PCR) and studied by single-stranded conformation polymorphism(SSCP)  analysis and direct DNA sequencing. ","firstTestingMethod":"Sanger sequencing","previousTesting":false,"secondTestingMethod":"Restriction digest","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/112a01d9-0b53-440d-9b9d-74eb7eea68ff_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10622252","allele":{"id":"https://genegraph.clinicalgenome.org/r/f9e4539c-7a79-47e9-8498-92f6c266dfe4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0003635","obo:HP_0003712","obo:HP_0003124","obo:HP_0000831","obo:HP_0001397"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/72a8cf92-f6e6-4710-be34-ec67bbda874c"}},{"id":"https://genegraph.clinicalgenome.org/r/cc25dd86-454c-467a-997f-974c5ccb323e_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16412238","rdfs:label":"Francis family 1","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/cc25dd86-454c-467a-997f-974c5ccb323e","type":"Family","rdfs:label":"Francis family 1","cg:modeOfInheritance":"Autosomal dominant/X-linked"},"meetsInclusionCriteria":false,"phenotype":[{"id":"obo:HP_0003712"},{"id":"obo:HP_0003635"},{"id":"obo:HP_0003124"},{"id":"obo:HP_0001397"},{"id":"obo:HP_0000831"}],"phenotypePositiveAllelePositive":2},{"id":"https://genegraph.clinicalgenome.org/r/7d4bc679-c88b-4c34-adfd-8394e97831ba_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17011503","rdfs:label":"Agostini family S2","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/7d4bc679-c88b-4c34-adfd-8394e97831ba","type":"Family","rdfs:label":"Agostini family S2","member":{"id":"https://genegraph.clinicalgenome.org/r/30dbbb15-8ca8-4c66-b8ba-b01aff677f19","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17011503","rdfs:label":"Agostini proband S2","allele":{"id":"https://genegraph.clinicalgenome.org/r/d8964eb1-cecd-4c8e-972b-909e570199d7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.386G>A (p.Cys129Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351618215"}},"detectionMethod":"The PPP1R3A (exons 1-4) and PPARγ (exons 1-6) and promoter region of PPARγ4 genes were PCR amplified using specific primers.","firstTestingMethod":"Sanger sequencing","previousTesting":false,"secondTestingMethod":"Genotyping","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d98723e1-87d2-446e-8a2b-a0deac38b30e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17011503","allele":{"id":"https://genegraph.clinicalgenome.org/r/d8964eb1-cecd-4c8e-972b-909e570199d7"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"}},"zygosity":{"id":"cg:MonoallelicHeterozygous"}},"cg:modeOfInheritance":"Autosomal dominant/X-linked"},"meetsInclusionCriteria":false,"phenotypeFreeText":"\nHypertriglyceridemia, Insulin resistance, Loss of facial adipose tissue, Insulin-resistant diabetes mellitus, Hypercholesterolemia, Acanthosis nigricans, Loss of gluteal subcutaneous adipose tissue ","phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0000831","obo:HP_0005978","obo:HP_0000855","obo:HP_0000956","obo:HP_0000292","obo:HP_0002155","obo:HP_0003124"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/30dbbb15-8ca8-4c66-b8ba-b01aff677f19"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.7},{"id":"https://genegraph.clinicalgenome.org/r/fdbae04a-dd54-42f0-a910-8db2ff1c7336_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/efbab74d-3e7b-471a-8fe4-efd6cedf9fc3","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/efbab74d-3e7b-471a-8fe4-efd6cedf9fc3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34168618","allele":{"id":"https://genegraph.clinicalgenome.org/r/a0dfe35e-692b-4819-8aca-65aed8cee514","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.380A>G (p.Glu127Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351618202"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/fdbae04a-dd54-42f0-a910-8db2ff1c7336","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34168618","rdfs:label":"Lambadiari proband 1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":29,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a0dfe35e-692b-4819-8aca-65aed8cee514"},"detectionMethod":"A genomic analysis for lipodystrophy panel genes was performed and included sequencing and deletion/duplication analysis. Genes: ADRA2A, AGPAT2, AKT2, BSCL2, CAV1, CAVIN1,\nCIDEC, FBN1, KCNJ6, LIPE, LMNA, LMNB2, PCYT1A, PIK3R1, PLIN1, POLD1, PPARG, PSMB8 and ZMPSTE24.","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0000831","obo:HP_0000842","obo:HP_0000292","obo:HP_0002155","obo:HP_0003124","obo:HP_0000822","obo:HP_0000956","obo:HP_0000855","obo:HP_0009017"],"previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/efbab74d-3e7b-471a-8fe4-efd6cedf9fc3_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/1fb38743-e7dc-4b29-a135-481706bd0582_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1489bb79-f3ad-4588-8881-3772ec878ecc","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1489bb79-f3ad-4588-8881-3772ec878ecc_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/1fb38743-e7dc-4b29-a135-481706bd0582"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/599f7698-0ad1-4530-a2a4-8e99b298c6ad_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8c7614b4-9945-421b-a310-a670a6a3129d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8c7614b4-9945-421b-a310-a670a6a3129d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro transfection assays using reporter constructs containing either synthetic {(PPARE)3 TKLUC} or natural (human FABP4-LUC) enhancer/promoter elements, the R308P mutant exhibit negligible basal transcriptional activity and minimal responsiveness with PGJ2. However, moderate (100nM farglitazar) or higher concentrations (1µM rosiglitazone; 10µM pioglitazone) of synthetic agonists restored transcriptional activity comparable to wild type receptor. \n\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/8c7614b4-9945-421b-a310-a670a6a3129d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29622583","allele":{"id":"https://genegraph.clinicalgenome.org/r/a6cc9d9f-c0de-448a-b2a8-4480b0066196","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.833G>C (p.Arg278Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351619330"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/599f7698-0ad1-4530-a2a4-8e99b298c6ad","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29622583","rdfs:label":"Agostini  Proband 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":16,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a6cc9d9f-c0de-448a-b2a8-4480b0066196"},"detectionMethod":"DNA from the patient, his mother and siblings was sequenced for the PPARG and LMNA genes.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0003712","obo:HP_0003635","obo:HP_0000831","obo:HP_0003124","obo:HP_0001397"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/8c7614b4-9945-421b-a310-a670a6a3129d_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b660a33b-d7a8-4094-a566-5402351f9663_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/18beee2a-78dd-4ef3-bc53-b44411fb9eaf","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/18beee2a-78dd-4ef3-bc53-b44411fb9eaf_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro translated C162W mutant lacking DNA binding, transcriptional, and dominant-negative activity","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/18beee2a-78dd-4ef3-bc53-b44411fb9eaf_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b660a33b-d7a8-4094-a566-5402351f9663"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5be60c3a-f857-4ab8-a41b-72a7768a7755_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c4d1786d-ff9a-4fea-a78e-25d62d9883e1","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c4d1786d-ff9a-4fea-a78e-25d62d9883e1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro studies have shown  that the PPARg- F388L mutation reduces the in vitro affinity of the receptor for its ligand rosiglitazone and decreases transcriptional activity in the absence of exogenous rosiglitazone.  The F388L mutation lacks dominant-negative activity.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/c4d1786d-ff9a-4fea-a78e-25d62d9883e1_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5be60c3a-f857-4ab8-a41b-72a7768a7755"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f00de897-9852-4966-9486-bbc718f78e93_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/44bef950-c412-4258-8ac1-716025b62a71","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/44bef950-c412-4258-8ac1-716025b62a71_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro analysis of the mutant protein showed that Arg194Trp (and Arg164Trp in NM_138711.6) did not bind to DNA and had no transcriptional activity. Also, R194W does not have any dominant-negative activity. This reduced DNA binding activity and haploinsufficiency lead to the clinical manifestations of FPLD3 and associated metabolic disorders.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/44bef950-c412-4258-8ac1-716025b62a71_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17299075","allele":{"id":"https://genegraph.clinicalgenome.org/r/c30cd0aa-afdd-440f-a1c3-217a24279dda","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.490C>T (p.Arg164Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119332"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f00de897-9852-4966-9486-bbc718f78e93","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17299075","rdfs:label":"Monajemi Proband ","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/c30cd0aa-afdd-440f-a1c3-217a24279dda"},"detectionMethod":"DNA sequencing of LMNA and PPARG gene plus more than 100bp at intron - exon boundaries and approximately 700 bp of the promoter.","firstTestingMethod":"PCR","phenotypeFreeText":"Lipohypertrophy in face, neck, trunk, and central adipose stores, diabetes, insulin resistance,   acanthosis nigricans, and hypertriglyceridemia, sometimes associated with pancreatitis and eruptive xanthomata.","phenotypes":["obo:HP_0003635","obo:HP_0001397","obo:HP_0003712","obo:HP_0000831","obo:HP_0003124"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/44bef950-c412-4258-8ac1-716025b62a71_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ca37cdd4-cc9a-481d-ba55-8ff3a316de21_proband_score_evidence_line","type":"EvidenceLine","direction":"Inconclusive","specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/a1d7bf7c-bb71-483e-9e13-bba6d4bf23cd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d6180eef-2c27-4fa2-b149-6f68c4bd390e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d6180eef-2c27-4fa2-b149-6f68c4bd390e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"A highly conserved missense mutant C114R in the DNA binding domain of PPARg showed reduced ligand dependent transactivation and DNA binding properties.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d6180eef-2c27-4fa2-b149-6f68c4bd390e_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a1d7bf7c-bb71-483e-9e13-bba6d4bf23cd"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9577616e-ed7f-46e0-b3f8-ec120b1796db_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1ebdd164-e673-4507-ae1b-652a11132f1c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1ebdd164-e673-4507-ae1b-652a11132f1c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":" to support, please describe functional data\tIn vitro transfection assays using reporter constructs containing either synthetic {(PPARE)3 TKLUC} or natural (human FABP4-LUC) enhancer/promoter elements, The Ala261Glu mutant exhibit negligible basal transcriptional activity and minimal responsiveness with PGJ2. However, moderate (100nM farglitazar) or higher concentrations (1µM rosiglitazone; 10µM pioglitazone) of synthetic agonists restored transcriptional activity comparable to wild type receptor.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1ebdd164-e673-4507-ae1b-652a11132f1c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29622583","allele":{"id":"https://genegraph.clinicalgenome.org/r/b5862379-b779-47ee-a27f-b444e73be9a6"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9577616e-ed7f-46e0-b3f8-ec120b1796db","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29622583","rdfs:label":"Agostini  Proband 3","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":30,"allele":{"id":"https://genegraph.clinicalgenome.org/r/b5862379-b779-47ee-a27f-b444e73be9a6"},"detectionMethod":"DNA from the patient was sequenced for the PPARG and LMNA genes.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0003635","obo:HP_0001397","obo:HP_0003124","obo:HP_0003712","obo:HP_0000831"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/1ebdd164-e673-4507-ae1b-652a11132f1c_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/96901dd9-0c3c-4703-954d-5c0b1cbe8257_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3379ec50-399d-4b82-af96-28e9efcb243e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3379ec50-399d-4b82-af96-28e9efcb243e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The mutant (Arg425Cys) shows strongly reduced transcriptional activity compared with wild-type PPARg with out dominant-negative effect. Structural analysis provides a possible explanation of how this mutation of a conserved residue in a patient with FPLD3 disrupts the function of the adipogenic transcription factor PPARgamma on multiple levels(PMID: 17312272)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3379ec50-399d-4b82-af96-28e9efcb243e_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/96901dd9-0c3c-4703-954d-5c0b1cbe8257"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6395d6cf-df8e-4c31-9a09-95a9f077254c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8dc7a6c4-6cf2-4577-9bfd-72a83e81b17e","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8dc7a6c4-6cf2-4577-9bfd-72a83e81b17e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"invitro translated R357X mutant lacks DNA binding, transcriptional activity compared to WT","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/8dc7a6c4-6cf2-4577-9bfd-72a83e81b17e_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/6395d6cf-df8e-4c31-9a09-95a9f077254c"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/72a8cf92-f6e6-4710-be34-ec67bbda874c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/112a01d9-0b53-440d-9b9d-74eb7eea68ff","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/112a01d9-0b53-440d-9b9d-74eb7eea68ff_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant receptor (P467L )showed a markedly right-shifted activation profile when tested with a reporter gene containing a PPAR response element and increasing concentrations of the thiazolidinedione ligand BRL49653((Fig 2b) ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/112a01d9-0b53-440d-9b9d-74eb7eea68ff_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/72a8cf92-f6e6-4710-be34-ec67bbda874c"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/30dbbb15-8ca8-4c66-b8ba-b01aff677f19_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d98723e1-87d2-446e-8a2b-a0deac38b30e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d98723e1-87d2-446e-8a2b-a0deac38b30e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"A highly conserved missense mutant C131Y in the DNA binding domain of PPARg showed reduced ligand dependent transactivation and DNA binding properties.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d98723e1-87d2-446e-8a2b-a0deac38b30e_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/30dbbb15-8ca8-4c66-b8ba-b01aff677f19"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b377720c-649c-4f58-b140-676e9de4fc64_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b75b5f2-d517-4890-a8ce-dabc56d6e4f3","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b75b5f2-d517-4890-a8ce-dabc56d6e4f3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16965332","allele":{"id":"https://genegraph.clinicalgenome.org/r/7475b02a-fc3e-4fb0-a6ae-a41f464adfd2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.323_326del (p.Glu108ValfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2586971778"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/b377720c-649c-4f58-b140-676e9de4fc64","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16965332","rdfs:label":"Hegele proband II-2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":37,"allele":{"id":"https://genegraph.clinicalgenome.org/r/7475b02a-fc3e-4fb0-a6ae-a41f464adfd2"},"detectionMethod":"DNA sequencing for PPARG and LMNA genes. Mutliple family members were genotyped the mutation by electrophoresis of the exon 2 amplicon in 12% polyacrylamide gel. Homozygotes for the wild-type sequence had a single 336 bp band, while the proband had an additional band size, 336 and 332 bp.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001397","obo:HP_0003635","obo:HP_0000831","obo:HP_0003712","obo:HP_0003124"],"previousTesting":false,"secondTestingMethod":"Genotyping","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/0b75b5f2-d517-4890-a8ce-dabc56d6e4f3_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/0c3e2edd-b494-4426-b997-4910c0ac0aee_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/360ca6b0-007c-405d-9416-f18cb2ca9148","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/360ca6b0-007c-405d-9416-f18cb2ca9148_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Leucine 339 is conserved among PPARγ species and in PPARα and δ. The nonsense L339X mutation predicted a protein truncation within the central part of the LBD. In HEK-293 cells transfected with L339X mutant PPARγ, the basal PPARγ transcriptional activity was significantly decreased (by 70%–80%) as compared with that measured in cells transfected with WT PPARγ. \nL339X-mutant PPARγ failed to significantly suppress WT-driven transcription, indicating that this mutant lacks dominant negative activity and acts through a  haploinsufficiency mechanism.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/360ca6b0-007c-405d-9416-f18cb2ca9148_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/0c3e2edd-b494-4426-b997-4910c0ac0aee"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/cfeeaaf4-1540-4e32-9d8c-3864e7892740_proband_score_evidence_line","type":"EvidenceLine","direction":"Inconclusive","specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/25564d13-fcc9-4c77-bdd0-0419ac5a0099_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c471b547-8523-4617-9aa3-7de15a030b0e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c471b547-8523-4617-9aa3-7de15a030b0e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The novel mutation E157D changes an amino acid in the DNA-binding site of PPARγ, and results in reduced activation of a wide range of classical PPARγ target genes with normal DNA binding and no dominant negative effect.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/c471b547-8523-4617-9aa3-7de15a030b0e_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/25564d13-fcc9-4c77-bdd0-0419ac5a0099"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e00a6480-22ca-4e02-a57a-7b677ccca70c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3bd7a224-2e48-44bf-9693-790a45953c91","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3bd7a224-2e48-44bf-9693-790a45953c91_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24980513","allele":{"id":"https://genegraph.clinicalgenome.org/r/7475b02a-fc3e-4fb0-a6ae-a41f464adfd2"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:BiallelicCompoundHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e00a6480-22ca-4e02-a57a-7b677ccca70c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24980513","rdfs:label":"Dyment Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":7,"allele":{"id":"https://genegraph.clinicalgenome.org/r/7475b02a-fc3e-4fb0-a6ae-a41f464adfd2"},"detectionMethod":"Direct sequencing was performed with dideoxynucleotide chain termination with the designed primers for PPARG,LMNA,AGPAT2 or BSCL2 genes.","firstTestingMethod":"PCR","phenotypeFreeText":"congenital generalized lipodystrophies commonly present with a general lack of adipose tissue noted in early life. Individuals also develop diabetes with insulin resistance, hypertriglyceridemia and some forms can show vitamin D resistance, cardiomyopathy and mild intellectual\ndisability.","phenotypes":["obo:HP_0003712","obo:HP_0000831","obo:HP_0001397","obo:HP_0003124","obo:HP_0003635"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3bd7a224-2e48-44bf-9693-790a45953c91_variant_evidence_item"},"zygosity":{"id":"cg:BiallelicCompoundHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/bf771d77-94ae-4fa9-a0db-06a9101b31a9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/73c008ef-6381-42af-8b68-3589ad876b7d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/73c008ef-6381-42af-8b68-3589ad876b7d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35422762","allele":{"id":"https://genegraph.clinicalgenome.org/r/a603e7d9-7d8e-4c7a-b1ef-95be143c6d6f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_138711.6(PPARG):c.839T>C (p.Phe280Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351619341"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/bf771d77-94ae-4fa9-a0db-06a9101b31a9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35422762","rdfs:label":"Chen Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":16,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a603e7d9-7d8e-4c7a-b1ef-95be143c6d6f"},"detectionMethod":"The genomic DNA of the patient, parents and siblings was extracted and whole exome sequencing was performed using HiSeq2500.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Exome sequencing","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/73c008ef-6381-42af-8b68-3589ad876b7d_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/faf2beb8-3d8c-43d1-a5a5-f998e2a46532_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3c21cc79-414f-4ae4-a6d7-e157b1305f8f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3c21cc79-414f-4ae4-a6d7-e157b1305f8f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional analyses of D424N PPARG showed a significantly reduced transcriptional activity compared with wild-type PPARG without any negative effect of D424N PPARG on the\nactivity of the wild-type protein. This confirms with previous observations that haploinsufficiency with a reduction of the abnormal protein’s transcriptional activity >50% is sufficient to cause\npartial lipodystrophy.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3c21cc79-414f-4ae4-a6d7-e157b1305f8f_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/faf2beb8-3d8c-43d1-a5a5-f998e2a46532"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/b4c76c1c-7e8a-418f-ba62-b7eeb3c3d472_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b4c76c1c-7e8a-418f-ba62-b7eeb3c3d472_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f650541e-8579-470c-85a4-3812f586b0fd","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dd079d3d-2871-4d04-a12b-5d1f24cdb06a","type":"FunctionalAlteration","dc:description":"Compared with the activity of cells transfected with wild‐type PPARγ cDNA, transcriptional activity did not decrease when D424N PPARγ cDNA was added. Thus, the mutant protein did not interfere with the wild‐type receptor activity.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17766367","rdfs:label":"Transactivation assay"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/422d60d8-c853-4c1b-9a8f-776cff3c7318","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7d82ee60-4e3f-46ff-b6c9-15b0ffcc84b5","type":"FunctionalAlteration","dc:description":"The E157D mutation on PPARγ1 transcriptional activity, human adiponectin PPRE was inserted into the minimal TK promoter upstream of the luciferase reporter gene, was showed reduced transcriptional activation compared with WT in 3T3 cells. Similar results were obtained for the other three PPRE sequences.  ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22750678","rdfs:label":"Transcriptional assay"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/62946f9a-6f49-45b1-b5f1-b68ab524fba1","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/44ffb3c6-4b36-4595-99ee-f867c0a12523","type":"FunctionalAlteration","dc:description":"In the absence of ligand, the transcriptional activity of the mutant receptor was 3.1-fold lower than the wild-type receptor. However, both wild-type and mutant receptors showed similar transcriptional activity in the presence of a saturating amount of the synthetic PPARg ligand rosiglitazone.  Similar findings were observed when this same experiment was replicated in the another murine C2C12 myoblast cell line. Western blot analysis revealed no decrease in F388L expression. However,  the F388L mutation lacks dominant-negative activity against the wild-type receptor.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12453919","rdfs:label":"Transcriptional assay"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6574e6b6-f7be-4d8a-8f4a-5bd389ced294","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a44c82eb-56ec-4d75-ba05-5c513e53bb7c","type":"FunctionalAlteration","dc:description":"The transcriptional activity of the Leu451Pro mutant on a reporter construct containing three copies of a consensus PPRE (3xPPRE) -Tk-Luc was significantly impaired under both basal and induced conditions compared to the WT protein in U2OS and HEK293T cells. Increasing Leu451Pro protein concentrations led to a proportional increase in transcriptional activity, but the mutant never reached WT levels. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26119484","rdfs:label":"Transactivation assay"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/b4c76c1c-7e8a-418f-ba62-b7eeb3c3d472_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/65fd7c48-048d-4f41-a49d-fcd491d67fda","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/403ce7b2-eec5-4c1d-a573-551ae3d2415e","type":"Finding","dc:description":"The mechanism underlying the disease association in affected heterozygotes is haploinsufficiency rather than dominant negative interference of the function of the normal allele product","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16412238","rdfs:label":"Transcriptional assay","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/373a95db-968f-497f-836d-f5bea82be5d3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c06be834-df07-494c-bf5e-317d93ce4959","type":"Finding","dc:description":"The Arg194Trp mutation in PPARG disrupts its DNA binding activity and through haploinsufficiency leads to clinical manifestation of FPLD3 and the associated metabolic disturbances.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17299075","rdfs:label":"EMSA and transactivation assay","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ae2e4c67-fc7a-492b-b1d0-8dfdd5c024a1","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/02f930ca-fc69-447b-8d42-7b16bc88331e","type":"Finding","dc:description":"PPAR-γ and RXR-α form an asymmetric complex that allows the ligand-binding domain (LBD) of PPAR-γ to interact with multiple domains on both proteins. The position of L451P in the LBD suggests that it can potentially disrupt intermolecular interactions, such as ligand-mediated cofactor interactions and/or RXRa heterodimerisation. In vitro binding assays show that mutation of L451 to proline affects heterodimerization with RXRα.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26119484","rdfs:label":"Electrophoretic Mobility Shift Assay (EMSA) ","demonstrates":{"id":"obo:MI_0935"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f206ff10-70b0-4cab-a8e0-fe09e38bdefe","type":"EvidenceLine","dc:description":"PPARg shown to be highly expressed in adipose or fat tissue via RNA-Seq; https://www.ncbi.nlm.nih.gov/gene/5468","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8a253cd4-badc-4bff-b63f-0617b1cce178","type":"Finding","dc:description":"detected via RNA-Seq; https://www.ncbi.nlm.nih.gov/gene/5468","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24309898","rdfs:label":"PPARg Expression-NCBI gene","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4}],"evidenceStrength":"Definitive","sequence":8815,"specifiedBy":"GeneValidityCriteria10","strengthScore":16,"subject":{"id":"https://genegraph.clinicalgenome.org/r/FpPYd0cUfew","type":"GeneValidityProposition","disease":"obo:MONDO_0006573","gene":"hgnc:9236","modeOfInheritance":"obo:HP_0032113"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_b4c76c1c-7e8a-418f-ba62-b7eeb3c3d472-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}